Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04891237 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Efficacy and Safety Evaluation for the Treatment of Allergy Against Grass and Olive Pollen

StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated May 7, 2025 (before its estimated January 2026 completion). Its status may not reflect the trial's current state.

Record History

See every version on ClinicalTrials.gov ↗

  1. Study sites: 26 to 32
    • Primary completion date: Oct 2025 to Jan 2026
    • Study completion date: Jan 2026 to Jan 2027
    v8
  2. Primary completion date: Oct 2023 to Oct 2025
    • Study sites: 22 to 26
    • Study completion date: Jan 2024 to Jan 2026
    • Secondary endpoints: details revised at 1 of 10 entries
    v7
  3. Study sites: 23 to 22v6
  4. Primary completion date: Dec 2022 to Oct 2023
    • Study sites: 20 to 23
    • Study completion date: Apr 2023 to Jan 2024
    • Eligibility criteria expanded, about 43 words
    v5
  5. Re-verified, no change to tracked fieldsv4
Show 2 earlier versionsHide 2 earlier versions
  1. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 16 to 20
    • Start date changed from estimate of May 2021 to Jun 14, 2021
    v3
  2. Secondary endpoints: details revised at 1 of 10 entriesv2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Inmunotek S.L.
10 trials monitored
See all monitored trials
Asthma
956 trials monitored
See 34 trials at risk
Prospective, multicenter, randomized, double-blind, placebo-controlled clinical trial of efficacy and safety with subcutaneous immunotherapy in patients with mild to moderate rhinitis / rhinoconjunctivitis with or without mild to moderate asthma sensitized to grasses and olive
Trial Details
NCT Number NCT04891237
Lead Sponsor Inmunotek S.L.
Conditions
(from sponsor)		 Rhinitis, Allergic, Rhinoconjunctivitis, Asthma, Allergic
Related terms Asthma, Hypersensitivity, Rhinitis, Allergic
Enrollment 180 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov